This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R.Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Current Medical Research and Opinion 24: 1609-1621, No. 6, 2008
Rights and permissions
About this article
Cite this article
Deferasirox dominates deferoxamine for iron control. Pharmacoecon. Outcomes News 556, 5 (2008). https://doi.org/10.2165/00151234-200805560-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805560-00013